6:02 AM ET
8-K
Business Update
NRX Pharmaceuticals Business Update
NRx Pharmaceuticals received notification from the FDA reclassifying a previously 'Major' amendment to its Abbreviated New Drug Application (ANDA) for preservative-free ketamine as a 'Minor' amendment. This reclassification accelerates the regulatory timeline, resulting in a revised GDUFA goal date of November 10, 2026.
- Counterparty
- FDA Office of Generic Drugs